Composition
-
CJC-1295 (Without DAC): 5 mg
-
Ipamorelin: 5 mg
-
Appearance: Lyophilized powder in a sealed research vial
Research Focus (non-clinical)
-
Comparative and combined pathway evaluation of GHRH analog + GHS agonist in in-vitro or ex-vivo models
-
Assessment of assay development, including chromatographic separation of co-formulated peptides
-
Stability characterization of a two-analyte lyophilized blend under laboratory storage conditions
Documentation
-
COA pending — third-party verification in progress
Important Notice
-
For research use only
-
Not for human consumption
-
Not intended to diagnose, treat, cure, or prevent any disease
